Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 30 09:30AM ET
15.49
Dollar change
-0.12
Percentage change
-0.76
%
CategoryGlobal or ExUS Equities - Industry Sector Asset TypeEquities (Stocks) TagsGlobal Return% 1Y-6.52% Shs Outstand Perf Week-0.13%
SponsorWisdom Tree ETF Type Tagsequity Return% 3Y- Total Holdings99 Perf Month-9.08%
Fund Family Bond Type Tagsbiotechnology Return% 5Y- AUM2.35M Perf Quarter-3.67%
IndexWisdomTree BioRevolution Index Average Maturity Tags- Return% 10Y NAV% Perf Half Y15.83%
Index Weighting Commodity Type Tags- Return% SI NAV/sh Perf Year-7.55%
Active/Passive Quant Type Tags- Flows% 1M0.00% 52W Range13.37 - 18.52 Perf YTD-8.14%
Dividend TTM0.14 (0.87%) ESG Type Tags- Flows% 3M-6.64% 52W High-16.37% Beta1.04
Dividend Ex-DateDec 22, 2023 Dividend Type Sector/Theme Flows% YTD-6.64% 52W Low15.83% ATR (14)0.25
Expense0.45% Structure Type Region Flows% 1Y RSI (14)41.28 Volatility1.13% 0.95%
Option/ShortYes / Yes Growth/Value Dev/Emerg Flows% 3Y Rel Volume0.01 Prev Close15.61
Inverse/Leveraged Market Cap Currency Flows% 5Y Avg Volume1.32K Price15.49
SMA20-2.29% SMA50-6.67% SMA200-3.93% Trades Volume1 Change-0.76%
WisdomTree BioRevolution Fund seeks to track the price and yield performance, before fees and expenses, of the WisdomTree BioRevolution Index ("index"). The fund generally uses a representative sampling strategy to achieve its investment objective, meaning it generally will invest in a sample of the securities in the index whose risk, return and other characteristics resemble the risk, return and other characteristics of the index as a whole. The index is designed to provide exposure to equity securities of exchange listed companies globally that will be significantly transformed by advancements in genetics and biotechnology. The fund is non-diversified.